# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 51-60 of 566 results.
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Oct 11, 2019
First Received: Jun 20, 2019
Disease(s): Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention(s): ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Mar 21, 2019
First Received: Nov 07, 2016
Disease(s): Diffuse Large B-cell Lymphoma (DLBCL)
Intervention(s): L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
Locations: Münster University Hospital, Münster, Germany
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Status: Recruiting
Last Changed: May 23, 2019
First Received: Sep 13, 2016
Disease(s): B Cell Lymphoma, Lymphoma
Intervention(s): Ixazomib, Lenalidomide, Rituximab
Locations: University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: May 24, 2019
First Received: Apr 01, 2015
Disease(s): Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Aug 12, 2019
First Received: Jan 05, 2018
Disease(s): Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention(s): Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders., Cyclophosphamide, Fludarabine
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Mayo Clinic Hospital, Phoenix, Arizona, United States
UC San Diego Moores Cancer Center, San Diego, California, United States
UCLA, Santa Monica, California, United States
... and 73 other locations.
Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma
Status: Recruiting
Last Changed: Oct 01, 2019
First Received: Jun 21, 2019
Disease(s): Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma
Intervention(s): CAR-CD19 T Cells
Locations: Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Apr 12, 2019
First Received: Mar 19, 2019
Disease(s): Lymphoma, B-Cell
Intervention(s): TAC01-CD19
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Oct 18, 2019
First Received: May 13, 2015
Disease(s): Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Intervention(s): Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
... and 268 other locations.
Indolent Non Follicular Lymphomas Prognostic Project
Status: Recruiting
Last Changed: Dec 31, 2018
First Received: Sep 19, 2016
Disease(s): Indolent B-Cell Lymphomas
Intervention(s): Any treatment, watch and wait policy included
Locations: Vienna Univ Med Int I, Vienna, Austria
Center of Hematology and Hemotherapy, UNICAMP, University of Campinas, Campinas, Brazil
Hospital das Clínicas Universidade Federal de Goiás, Goiania, Brazil
Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil
São Paulo-Santa Casa Medical School, São Paulo, Brazil
... and 57 other locations.
Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy
Status: Recruiting
Last Changed: Apr 23, 2019
First Received: Jun 26, 2018
Disease(s): Lymphoma, B-Cell
Intervention(s): nivolumab
Locations: Sheba medical organization, Ramat Gan, Israel